Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22184
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYare, Katrine-
dc.contributor.authorWoodward, Michael M-
dc.date2019-11-11-
dc.date.accessioned2019-12-04T04:59:39Z-
dc.date.available2019-12-04T04:59:39Z-
dc.date.issued2020-
dc.identifier.citationJournal of Alzheimer's disease : JAD 2020; 73(1): 23-37-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22184-
dc.description.abstractNumerous observational studies have suggested that hormone therapy (HT) might protect postmenopausal women against cognitive decline and Alzheimer's disease (AD). However, because of the significant disparity between results, especially those between observational and randomized controlled trials (RCT), this postulate remains unproven. A significant contributing factor to these inconsistencies is the loose use of the generic definitions of estrogens and progestogens with most studies not delineating the clear differences between non-endogenous and endogenously identical (bioidentical) hormones, their molecular binding affinities and actions, and resultant metabolites. This is highlighted by the generalized terminological use of HT, which is often used to encompass significantly disparate hormonal formulations without clear demarcation. This has impacted and continues to significantly influence interpretations of data, meta-analyses, observational studies, etc., relevant to AD. To progress forward and allow unbiased interpretation, it is no longer acceptable to group HT formulations together as a homogenous group. This will also allow differentiation between compounds that exhibit beneficial actions and those that do not and whether these effects are specific or generalized. The role of the endogenous hormones, 17 beta-oestradiol (E2) and progesterone (P4), in the development of sporadic AD in postmenopausal women is also examined.-
dc.language.isoeng-
dc.subject17 beta-oestradiol-
dc.subjectAlzheimer’s disease-
dc.subjectconjugated equine estrogens-
dc.subjecthormone therapy-
dc.subjectprogesterone-
dc.subjectprogestins-
dc.titleHormone Therapy and Effects on Sporadic Alzheimer's Disease in Postmenopausal Women: Importance of Nomenclature.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of Alzheimer's disease : JAD-
dc.identifier.affiliationHeidelberg Repatriation Hospital, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.3233/JAD-190896-
dc.identifier.pubmedid31744009-
dc.type.austinJournal Article-
local.name.researcherWoodward, Michael M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptAged Care-
crisitem.author.deptGeriatric Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

138
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.